OncoMatch/Clinical Trials/NCT06525220
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Is NCT06525220 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Petosemtamab and Pembrolizumab for head and neck squamous cell carcinoma.
Treatment: Petosemtamab · Pembrolizumab — This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (cps ≥1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy for incurable recurrent or metastatic disease
should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting
Lab requirements
Blood counts
Adequate organ function as defined per protocol.
Kidney function
Adequate organ function as defined per protocol.
Liver function
Adequate organ function as defined per protocol.
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Adequate organ function as defined per protocol. Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 164 · Mobile, Alabama
- Site 36 · La Jolla, California
- Site 27 · Los Angeles, California
- Site 16 · Palo Alto, California
- Site 19 · Newark, Delaware
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06525220 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for incurable recurrent or metastatic disease disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify